With the evolving landscape of adjuvant treatment, there is a need for greater knowledge regarding the outcomes of patients with resected early-stage NSCLC that harbor actionable genomic alterations other than EGFR and ALK. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.